225 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Fifth Third Wealth Advisors LLC

Fifth Third Wealth Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 225 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Several other large investors have also recently bought and sold shares of REGN. Eudaimonia Advisors LLC raised its position in Regeneron Pharmaceuticals by 1.2% in the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 11 shares during the last quarter. Drive Wealth Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.0% in the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 12 shares during the period. MCF Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. LCM Capital Management Inc increased its stake in shares of Regeneron Pharmaceuticals by 2.5% in the fourth quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock valued at $427,000 after buying an additional 12 shares during the period. Finally, TrinityPoint Wealth LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.8% in the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 12 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of several recent research reports. Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target for the company. Truist Financial reissued a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Finally, Argus raised their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $1,015.91.

Regeneron Pharmaceuticals Stock Up 0.0 %

Shares of REGN stock traded up $0.17 during trading hours on Friday, reaching $1,051.03. The company had a trading volume of 737,058 shares, compared to its average volume of 480,121. Regeneron Pharmaceuticals, Inc. has a 12 month low of $688.52 and a 12 month high of $1,081.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The business has a fifty day simple moving average of $978.05 and a 200-day simple moving average of $948.28. The company has a market cap of $115.81 billion, a price-to-earnings ratio of 31.04, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. Insiders have sold 61,971 shares of company stock worth $61,217,654 over the last 90 days. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.